Document Detail


Advancing management of hypertension through pharmacogenomics.
MedLine Citation:
PMID:  22713143     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypertension is the most common, chronic disease in the world, and there are many effective pharmacological agents available for its treatment. Despite the plethora of treatment options, data across the globe suggest that blood pressure control rates are < 50%, a fact likely influenced in part by the inability to predict the antihypertensive drug likely to be most effective for an individual patient. Pharmacogenomics in hypertension holds the promise of identifying genetic biomarkers for antihypertensive drug response, which might be used in the future in treatment selection. Research in the field is also likely to enhance our understanding of hypertension and the mechanisms by which the various drugs produce efficacy. There are several examples in the literature of genes with relatively strong data on associations of genetic polymorphisms with antihypertensive response; the data on ADRB1, CACNB2, and NEDD4L are detailed as examples. Substantial additional data in hypertension pharmacogenomics are expected to be forthcoming from recently completed genome-wide association studies. Increased collaboration among research groups will help insure successful discoveries from these large-scale studies. The next decade should clearly define the potential clinical implications of the research in hypertension pharmacogenomics that is currently in progress.
Authors:
Julie A Johnson
Related Documents :
12648163 - Effects of sex, gonadectomy, and oestrogen substitution on ischaemic preconditioning an...
1308473 - Protection of isolated perfused working rat heart from oxidative stress by exogenous l-...
22243793 - The combined ratios of l-arginine and asymmetric and symmetric dimethylarginine as biom...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annals of medicine     Volume:  44 Suppl 1     ISSN:  1365-2060     ISO Abbreviation:  Ann. Med.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-06-20     Completed Date:  2012-11-28     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  8906388     Medline TA:  Ann Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  S17-22     Citation Subset:  IM    
Affiliation:
Colleges of Pharmacy and Medicine and Center for Pharmacogenomics, University of Florida, Gainesville, Florida 100486, USA. Johnson@cop.ufl.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Pressure / drug effects,  genetics
Calcium Channels, L-Type / genetics
Endosomal Sorting Complexes Required for Transport / genetics
Humans
Hypertension / drug therapy*,  genetics*
Pharmacogenetics*
Polymorphism, Genetic
Receptors, Adrenergic, beta-1 / genetics
Ubiquitin-Protein Ligases / genetics
Grant Support
ID/Acronym/Agency:
U01 GM074492/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/ADRB1 protein, human; 0/CACNB2 protein, human; 0/Calcium Channels, L-Type; 0/Endosomal Sorting Complexes Required for Transport; 0/Receptors, Adrenergic, beta-1; EC 6.3.2.19/Nedd4 ubiquitin protein ligases; EC 6.3.2.19/Ubiquitin-Protein Ligases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Telomere length and cardiovascular aging.
Next Document:  Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies.